RedC Biotech Ltd.’s Post

🌟 Breakthrough in Biotech! 🚀 Limula secures a transformative $6.8M to expedite a novel cell therapy production platform. This Swiss life science start-up is redefining stem cell manufacturing, integrating a bioreactor and centrifuge into a single unit—it's cost-efficient and a game-changer for CAR-T cell therapies. The challenges have been immense. With high costs and complex processes, cell therapy production has been an uphill battle. But Limula's leap in automation offers scalability and a much-needed shift toward digital traceability. CEO Luc Henry envisions a future where sophisticated cell manipulation tools are not a luxury but the norm. Their technology paints a hopeful picture: complex therapies made accessible to the masses, not just the elite. Limula's approach is a beacon of innovation, supported by investors like LifeX Ventures. It's about time production techniques caught up with scientific advancements, and it looks like we're finally there. Capital will drive GMP compliance, pushing this promising platform into a future where life-saving therapies are within our grasp. This is just the beginning. #CellTherapy #Innovation #Biotech

This week's #RaiseoftheWeek is AI-first biotech startup, CellVoyant! They just raised £7.6m in Seed funding 🚀 ⚕ CellVoyant is a biotechnology company on a mission to cure chronic diseases. They use AI imaging technology to help developers of stem cell therapies more efficiently manufacture new treatments. The company plans to use part of its seed funding to grow its team, create its first business development & commercialisation department, automate internal processes, scale workflows and upgrade their lab space. Why we love CellVoyant: 💡 They’re working at the powerful intersection of cell biology, computer vision, engineering, and machine learning 💸 CellVoyant's technology could potentially reduce the cost of developing each stem cell therapy by $10m-100m 📈 They're efficient! They hit their R&D goals around readying their tech for commercialisation, “quicker than expected” says CEO Rafael Carazo Salas  The round was led by Octopus Ventures, with Horizons Ventures, Air Street Capital and Verve Ventures also participating. https://cellvoyant.com/

Finland’s StemSight gains access to CRISPR/Cas9 technology through collaboration with ERS Genomics for corneal blindness therapies Tampere-based StemSight - Vision Unlimited and US-based ERS Genomics have signed a non-exclusive agreement allowing StemSight access to ERS Genomics’ CRISPR/Cas9 patent portfolio. StemSight, a biotech company working on stem cell-based therapies for corneal blindness, considers this partnership a significant step forward. By using CRISPR/Cas9 technology, StemSight aims to address challenges in existing cell therapies and move closer to developing transformative treatments for patients with incurable blindness. ERS Genomics, a CRISPR licensing company, is pleased with the collaboration and acknowledges the growing importance of Finland in the global biotech and life science sector. The financial details of the agreement have not been disclosed. https://lnkd.in/dshEjPxU #community #partnerships #nordicmade #finland #CRISPR #biotech #healthtech #deeptech #medtech #trending

Witness the epitome of innovation meeting necessity in the realm of Cell & Gene Therapeutics (CGT). Imagine a future where Korean stem cell therapeutic developer #NSAGE inc, at the forefront of AI-based deep automation, joins forces with us at #Himedia, India. Our mission is to craft affordable, top-tier serum-free media and reagents, vital for CGT manufacturers. Imagine this collaboration as a symphony, harmonizing scalability and affordability—crucial for the future of therapeutics. As the vanguard of cell therapy, our partnership aims to cater to global patient needs. Thanks to leaders making this collaboration successful Dr. Rahul Joshi, Dr. Priti Warke, Dr. Bonghee Lee, Dr. Okjae Koo. Calling all CGT professionals: join us on this transformative journey. Connect with us to forge a path where pioneering solutions meet the demands of patients worldwide. Shape the future of healthcare; your journey begins here. #Stemcelltherapeutics, #Harmoni, #Stemcellmedia, #CARTherapy, #SerumFreeMedia, #Himedia, #CellBio

Mini Organs for the Future: Sci-Fi Hype or Medical Marvel? Here are the top 5 things you need to know: 1) Disruptive Tech, Huge Potential: This mini liver thing is a game-changer. Forget traditional transplants with their waiting lists and anti-rejection meds. LyGenesis injects donor cells into lymph nodes, turning them into mini-factories that filter blood. It's early days, but if successful, this could revolutionize end-stage liver disease treatment. 2) Addressing the Organ Shortage: We all know the organ donor crisis. LyGenesis might be the answer. They can potentially use livers that wouldn't be suitable for transplants, making more available for those who need them most. 3) Safety First: This is a first-in-human trial, and safety is paramount. The patient seems okay so far, but close monitoring is crucial. Anti-rejection drugs are a must with donor cells, but that opens doors for infections. 4) Beyond Livers? The holy grail here is the platform, not just livers. LyGenesis is testing this tech with kidneys and pancreases in animals. Imagine a future where failing organs are bypassed, not replaced! 5) Investment? Wait and See: This is exciting, but caution is wise. The human trial is small, and long-term effects are unknown. Let's see the phase II results before diving in. However, for the bold investor with a high-risk tolerance, LyGenesis could be a moonshot waiting to launch. The company closed a USD 20 M A-2 round last year led by Prime Movers Lab Bonus Insight: Ethical considerations are on the horizon. Could someone get their own stem cells used to grow mini-organs, eliminating the need for immunosuppression? What are your thoughts on this new and bold solution? Are you investing in these new technologies? Leave a comment below #biotech #investment #investor #vc #drug #discovery #healthcare #market #business #celltherapy Biotech investor or innovator? We help investors unlock potential by assisting with due diligence and companies refine strategies for success and fundraising. Let's chat! _________________________________________________________________________________ Have you enjoyed this? Recommend Repost ♻️ if you find it useful Follow me, hit the 🔔 Adrian Rubstein

🌟 Passion for Progress: Advancing Bioprocessing with gPROMS 🌟 Hello, LinkedIn community! I’m Michael, and I’m on a mission. 🚀 As someone living with a progressive form of Multiple Sclerosis (MS), I’ve faced challenges head-on. Last year, I underwent autologous stem cell therapy—a significant milestone in my journey. Despite the hurdles, I remain resilient and proud to be part of Siemens Industry Software. Why gPROMS? Because it’s more than software; it’s a catalyst for change. Let me tell you why: 1.) Empowering Scientists: By promoting gPROMS for formulated products, I connect with brilliant minds—scientists who hold the keys to groundbreaking therapies. Together, we explore CAR-T, inverse vaccination, and neural stem cells—the next frontier in MS treatment. 2.) Bioprocessing Revolution: Imagine designing and optimizing biomanufacturing processes without the constraints of traditional in vitro experiments. gPROMS offers that shortcut. Let’s harness its power to reduce risk, conserve resources, and enhance performance. 3.) Collaboration Across Disciplines: R&D, engineering, and manufacturing converge when we deploy product and process knowledge. Let’s bridge gaps, share insights, and drive innovation. 🌐 Calling All Scientists: Whether you’re in pharma, big process companies, or academia, let’s connect! Book a meeting with me here. https://lnkd.in/e6TWTRET Together, we’ll shape the future—one simulation at a time. 🌈 Let’s cure MS and transform lives! 💪 #Bioprocessing #Simulation #Innovation #MSWarrior

🦴 Osteoarthritis, a relentless joint disease affecting millions, may be defeated in the near future with the help of breakthrough research and development: Innovative therapies that rely on induced pluripotent stem cells (iPSCs) offer hope for structural repair, not just symptom relief. 📚 In our recent publication, Laura Herbst's team unveils the game-changing AutoCRAT system, which represents a major step forward in automation. This ensures scalable, high-quality and safe production, heralding a new era of accessible regenerative therapies. 👉 For more information, please read the full publication. 💡 Feel free to reach out to our experts with any questions or potential collaborations in this field. We're excited to explore new opportunities! Authors: Laura Herbst, Ferdinand Grote, Mary Murphy, Georgina Shaw, Bastian Nießing and Prof. Robert Schmitt Regenerative Medicine Institute (REMEDI) Werkzeugmaschinenlabor WZL der RWTH Aachen #StemCellResearch #Osteoarthritis #MedicalInnovation #RegenerativeTherapies

CellVoyant Secures £7.6M Funding for Groundbreaking AI-Enhanced Cell Imaging-John Pinching CellVoyant, a University of Bristol AI biotechnology spin-out, has secured £7.6 million in a funding round led by Octopus Ventures. The investment, with participation from Horizons Ventures, Air Street Capital, and Verve Group Ventures, will support the commercialization of CellVoyant's AI and live cell imaging platforms. The technology combines advanced AI with real-time live cell imaging to extract spatial and temporal information from millions of cells. This innovation aids scientists in understanding cell composition and predicting their evolution, particularly in the development of novel cell therapies. The funding will also be utilized to expand infrastructure, increase headcount, and support further research and development. Rafael E. Carazo Salas,Rickard Sjögren,Tünde Berecz, PhD,Evelyn Welch #CellVoyant #AI #Biotechnology #CellImaging #Funding #News #TrendingNews

Thanks BioSpace for covering this topic on #healthspan #longevity In early September, California-based Rejuvenation Technologies Inc. posted $10.6 million in seed financing, led by Khosla Ventures a firm headed by businessman and entrepreneur Vinod Khosla. Another $4.6 million in grant money brings the company’s initial funding to more than $15 million. Rejuvenation is looking to rewind the body’s molecular aging clock by targeting telomere shortening. The biotech’s platform is built around optimized telomerase mRNA encapsulated in custom tissue-targeted lipid nanoparticles. Its first target will be fibrotic lung diseases and liver cirrhosis—both conditions primarily diagnosed in people over 50. Another startup out of Cambridge, founded by a neurosurgeon, is harnessing human pluripotent stem cells for their regenerative capabilities. clock.bio broke out of the gates with $4 million in hand to pursue a validated “short cut” to reading the genetic codes specific to rejuvenation inside human cells, CEO Markus Gstöttner told BioSpace. In the next 12 months, Gstöttner said the company should be able to identify the most relevant genes to target new pathways to treat age-related disease.

In our recent video with Dr. Drew Taylor, he speaks with Dr. Sanjeev Goel about the world of stem cells and exosomes in regenerative medicine. 🔬🧬 In 2017, Dr. Drew Taylor co-founded Acorn Biolabs with the goal of making regenerative medicine more accessible and affordable for people. Acorn Biolabs specializes in non-invasive cell banking, allowing individuals to preserve their own cells for future regenerative treatments. 🧫 When it comes to developing cell-based therapies, there can be risks involved. That's why Dr. Taylor says the research and development process takes time. It's crucial that these cells are fully safe and have proper control mechanisms in place before delivering them to patients. 👫 While we wait for advancements in this field, the key is to focus on starting materials of the highest quality. 🚀 Learn more about the exciting progress in cell-based therapies in the full video. LINK IN BIO. . . . #CellTherapies #CancerResearch #QualityControl #StemCells #Biolabs #PeakHuman #DrewTaylor #LatestResearch